Brief: Homology Medicines Reports Q2 2022 Results

Q32 Bio

15/08/2022 21:13

Aug 15 (Reuters) - Homology Medicines Inc  FIXX.O :
    * HOMOLOGY MEDICINES REPORTS SECOND QUARTER 2022 FINANCIAL
RESULTS, RECENT HIGHLIGHTS AND PROVIDES BUSINESS UPDATE
    * Q2 LOSS PER SHARE $0.51
    * AS OF JUNE 30, 2022, HOMOLOGY HAD APPROXIMATELY $225.5
MILLION
IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS
    * HOMOLOGY MEDICINES - BASED ON CURRENT PROJECTIONS, WHICH
INCLUDE
 MODEST WORKFORCE REDUCTION , NOW EXPECTS CASH RESOURCES TO FUND
OPERATIONS INTO Q4 OF 2024
    * ANNOUNCED OPTIMIZED MLD GENE THERAPY DEVELOPMENT CANDIDATE
WITH
PLANS TO SEEK A PARTNER FOR PROGRAM
    * ON TRACK FOR UPDATES ON PHEEDIT AND JUMPSTART PROGRAMS BY
END OF
2022

Source text for Eikon:  ID:nGNX25SshC 
Further company coverage:  FIXX.O 

 ((Reuters.Briefs@thomsonreuters.com;))